C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
Posting of 2023 Annual Report and Notice of AGM
18 December 2023 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, announces that it has today published and posted to shareholders the Annual Report and Accounts for the year ended 31 July 2023 and Notice of the Annual General Meeting ("AGM") which will be held at Panmure Gordon, 40 Gracechurch Street, EC3V 0BT, on 23 January 2024 at 11.30 a.m. (GMT).
The Annual Report and Accounts and Notice of AGM are also available to view on, and download from, the Company's website at www.c4xdiscovery.com
- Ends -
Contacts
| C4X Discovery Holdings |
|
| Mo Noonan, Communications | +44 (0)787 6444977 |
| | |
| Panmure Gordon (UK) Limited (NOMAD and Broker) |
|
| Freddy Crossley, Emma Earl (Corporate Finance) | +44 (0)20 7886 2500 |
| Rupert Dearden (Corporate Broking) | |
|
|
|
| C4X Discovery Media - Consilium Strategic Communications |
|
| Mary-Jane Elliott, Chris Gardner, Matthew Neal | +44 (0)203 709 5700 |
Notes to Editors:
About C4X Discovery
C4X Discovery ("C4XD") is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world?leading medicines. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced candidate molecule design and patient stratification capabilities, generating small molecule drug candidates across multiple disease areas focused on immuno-inflammation. Our commercially attractive portfolio ranges from early-stage target opportunities to late-stage Drug Discovery programmes and we have three commercially partnered programmes with one candidate in clinical development.
For more information visit us at www.c4xdiscovery.com or follow us on twitter @C4XDiscovery.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.